About biolinerx - BLRX
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
BLRX At a Glance
BioLineRx Ltd.
Modi'in Technology Park
Modi'in, HaMerkaz 7177871
| Phone | 972-8-642-9100 | Revenue | 29.08M | |
| Industry | Pharmaceuticals: Major | Net Income | -9,264,764.67 | |
| Sector | Health Technology | 2024 Sales Growth | 507.343% | |
| Fiscal Year-end | 12 / 2025 | Employees | 28 | |
| View SEC Filings |
BLRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.588 |
| Price to Book Ratio | 1.417 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.818 |
| Enterprise Value to Sales | 0.432 |
| Total Debt to Enterprise Value | 1.196 |
BLRX Efficiency
| Revenue/Employee | 1,038,476.961 |
| Income Per Employee | -330,884.452 |
| Receivables Turnover | 7.527 |
| Total Asset Turnover | 0.566 |
BLRX Liquidity
| Current Ratio | 1.759 |
| Quick Ratio | 1.555 |
| Cash Ratio | 1.27 |
BLRX Profitability
| Gross Margin | 65.328 |
| Operating Margin | -67.028 |
| Pretax Margin | -31.862 |
| Net Margin | -31.862 |
| Return on Assets | -18.019 |
| Return on Equity | -69.44 |
| Return on Total Capital | -32.507 |
| Return on Invested Capital | -41.508 |
BLRX Capital Structure
| Total Debt to Total Equity | 111.73 |
| Total Debt to Total Capital | 52.77 |
| Total Debt to Total Assets | 38.657 |
| Long-Term Debt to Equity | 74.578 |
| Long-Term Debt to Total Capital | 35.223 |